Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Researchers reveal imaging technology could help diagnose and treat bowel cancer

Affecting over 250,000 people, bowel cancer is the fourth most common cancer in the UK

- PMLiVE

Early strategic planning: how to get ahead of the curve

By James Aird and Sarah Theobald

Amiculum

- PMLiVE

Thinking Different – a new campaign to welcome and celebrate neurodiversity across the UK healthcare communications industry

It is estimated that there are 50% more neurodivergent practitioners working in creative sectors, like healthcare communications, than in the general population

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia

The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL

- PMLiVE

FDA approves Orchard’s Lenmeldy gene therapy for metachromatic leukodystrophy

The rare genetic disease is estimated to affect one in every 40,000 people in the US

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

FDA approves Madrigal’s Rezdiffra as first drug for fatty liver disease NASH

Over six million people in the US are affected by NASH with moderate-to-advanced liver scarring

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

- PMLiVE

GSK’s Jemperli regimens demonstrate potential for wider endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links